Denmark· DK-28105167112
Votubia
A everolimus product containing everolimus, registered in Denmark by Novartis Europharm Limited. The same ATC class is registered in 11 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Everolimus is registered in 11 of 19 countries.
Countries holding a registration under ATC L01EG02 (everolimus), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 8 of them publish a price we can compare per daily dose
Everolimus · ATC L01EG02
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of everolimus costs, country by country.
Normalised to the WHO defined daily dose (10 mg), the median price runs from $27.93 in United States to $142.94 in Switzerland — a ×5.1 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Everolimus · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$142.94
- IT Italy$125.91
- ES Spain$105.57
- US United States$27.93 (acquisition cost)
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Everolimus
- Manufacturer
- Novartis Europharm Limited
- Country
- Denmark (DK)
- ATC code
- L01EG02
- ATC class
- Everolimus
- Defined daily dose
- 10 mg, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28105167112
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
428 interactions on record for everolimus.
Graded by severity as the source publishes them — 165 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Everolimus · interactions on record
428 records
- 165 severe
- 255 moderate
- 8 minor
Most severe, free to view
- AprepitantA04AD12severe
- NeomycinA07AA01severe
- StreptomycinA07AA04severe
- Polymyxin BA07AA05severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01EG02
Everolimus, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c69c72c3-d249-4970-b9cd-8f6d9486f617 GET /v1/drugs/c69c72c3-d249-4970-b9cd-8f6d9486f617?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "dispergible tabletter",
"source": "dkma",
"strength": "3 mg",
"auth_role": "MOD",
"dk_drugid": "28105167112",
"substance": "Everolimus",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "41593"
}See everything about everolimus.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.